Spatial Navigation in Preclinical Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Although several previous studies have demonstrated navigational deficits in early-stage symptomatic Alzheimer's disease (AD), navigational abilities in preclinical AD have not been examined. The present investigation examined the effects of preclinical AD and early-stage symptomatic AD on spatial navigation performance. Performance on tasks of wayfinding and route learning in a virtual reality environment were examined. Comparisons were made across the following three groups: Clinically normal without preclinical AD (n = 42), clinically normal with preclinical AD (n = 13), and early-stage symptomatic AD (n = 16) groups. Preclinical AD was defined based on cerebrospinal fluid Aβ42 levels below 500 pg/ml. Preclinical AD was associated with deficits in the use of a wayfinding strategy, but not a route learning strategy. Moreover, post-hoc analyses indicated that wayfinding performance had moderate sensitivity and specificity. Results also confirmed early-stage symptomatic AD-related deficits in the use of both wayfinding and route learning strategies. The results of this study suggest that aspects of spatial navigation may be particularly sensitive at detecting the earliest cognitive deficits of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988) · Biometrics · doi:10.2307/2531595 · Cited by 22,649 · cited 1×
“In the current study, the method of DeLong, DeLong, and Clarke-Pearson [64] was used to compare areas under the curve using the Sigmaplot program.”
A Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Self-citationMild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 4×
“A current conceptualization of the process of AD is that it occurs in stages from a preclinical phase to mild cognitive impairment (MCI) to symptomatic AD [6, 7].”
InfluentialSelf-citationJack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods
Jack, C. R., Bernstein, M. A., Fox, N. C., Thompson, P., Alexander, G., Harvey, D., Borowski, B., Britson, P. J., L. Whitwell, J., Ward, C., et al. (2008) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21049 · Cited by 4,347
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490 · cited 1×
“, parietal regions), respectively [8, 9].”
Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease
Minoshima, S., Giordani, B., Berent, S., Frey, K. A., Foster, N. L., & Kuhl, D. E. (1997) · Annals of Neurology · doi:10.1002/ana.410420114 · Cited by 1,802 · cited 1×
“For example, there is evidence of very early changes in medial parietal regions, including the posterior cingulate and retrosplenial cortex [27, 70, 71].”
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611 · cited 1×
“Although preclinical AD is characterized by both the formation of neurofibrillary tangles and amyloid plaques [10, 11], previous research indicates that changes in CSF A 42 may precede changes in CSF p-tau and tau, suggesting that CSF A 42 may be an earlier biomarker of AD pathology [53–56].”
Knowing Where and Getting There: A Human Navigation Network
Maguire, E. A., Burgess, N., Donnett, J. G., Frackowiak, R. S. J., Frith, C. D., & O'Keefe, J. (1998) · Science · doi:10.1126/science.280.5365.921 · Cited by 1,303
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans
Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246
Self-citationThe Well-Worn Route and the Path Less Traveled
Hartley, T., Maguire, E. A., Spiers, H. J., & Burgess, N. (2003) · Neuron · doi:10.1016/s0896-6273(03)00095-3 · Cited by 817
Pike, K. E., Savage, G., Villemagne, V. L., Ng, S., Moss, S. A., Maruff, P., Mathis, C. A., Klunk, W. E., Masters, C. L., & Rowe, C. C. (2007) · Brain · doi:10.1093/brain/awm238 · Cited by 789
Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease
Price, J. L., McKeel, D. W., Buckles, V. D., Roe, C. M., Xiong, C., Grundman, M., Hansen, L. A., Petersen, R. C., Parisi, J. E., Dickson, D. W., et al. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.04.002 · Cited by 661
Self-citationBerg, L., McKeel, D. W., Miller, J. P., Storandt, M., Rubin, E. H., Morris, J. C., Baty, J., Coats, M., Norton, J., Goate, A. M., et al. (1998) · Archives of Neurology · doi:10.1001/archneur.55.3.326 · Cited by 657
Self-citationSheline, Y. I., Raichle, M. E., Snyder, A. Z., Morris, J. C., Head, D., Wang, S., & Mintun, M. A. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.024 · Cited by 597
Self-citationPreclinical Alzheimer's disease and its outcome: a longitudinal cohort study
Vos, S. J., Xiong, C., Visser, P. J., Jasielec, M. S., Hassenstab, J., Grant, E. A., Cairns, N. J., Morris, J. C., Holtzman, D. M., & Fagan, A. M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70194-7 · Cited by 564 · cited 1×
“In addition, CN individuals with amyloid deposition demonstrate greater atrophy as well as an increased risk of cognitive decline and development of symptomatic AD [18–22].”
Self-citationAge differences in the formation and use of cognitive maps
Iaria, G., Palermo, L., Committeri, G., & Barton, J. J. S. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.08.040 · Cited by 231
Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later
Roe, C. M., Fagan, A. M., Grant, E. A., Hassenstab, J., Moulder, K. L., Maue Dreyfus, D., Sutphen, C. L., Benzinger, T. L. S., Mintun, M. A., Holtzman, D. M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182918ca6 · Cited by 222
Self-citationCerebrospinal fluid -amyloid 1-42 concentration may predict cognitive decline in older women
Gustafson, D. R., Skoog, I., Rosengren, L., Zetterberg, H., & Blennow, K. (2006) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.100529 · Cited by 214
Skoog, I., Davidsson, P., Aevarsson, Ó., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (2003) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000068478 · Cited by 194
Kalová, E., Vlček, K., Jarolímová, E., & Bureš, J. (2005) · Behavioural Brain Research · doi:10.1016/j.bbr.2004.10.016 · Cited by 131 · cited 1×
“Previous research indicates that navigation performance in virtual environments is equivalent to performance in real-world environments [38, 42, 57].”
Bellassen, V., Iglói, K., de Souza, L. C., Dubois, B., & Rondi-Reig, L. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.4556-11.2012 · Cited by 93 · cited 1×
“This generalized pattern extends to the observation that neither wayfinding nor route learning performance was significantly better at discriminating groups than an episodic memory task (but see [67] and [68] for evidence of the superiority of navigationrelated tasks to standard psychometric tasks).”
Cited by
Spatial navigation deficits — overlooked cognitive marker for preclinical Alzheimer disease?
Coughlan, G., Laczó, J., Hort, J., Minihane, A.-M., & Hornberger, M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0031-x · Cited by 500
Fu, H., Rodriguez, G. A., Herman, M., Emrani, S., Nahmani, E., Barrett, G., Figueroa, H. Y., Goldberg, E., Hussaini, S. A., & Duff, K. E. (2017) · Neuron · doi:10.1016/j.neuron.2016.12.023 · Cited by 264
“, 2013), including in preclinical AD (Allison et al., 2016), and the EC is known to play an important role in spatial navigation (Fyhn et al.”
Exercise and Hippocampal Memory Systems
Voss, M. W., Soto, C., Yoo, S., Sodoma, M., Vivar, C., & van Praag, H. (2019) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2019.01.006 · Cited by 235
Virtual reality in the diagnostic and therapy for mental disorders: A systematic review
Wiebe, A., Kannen, K., Selaskowski, B., Mehren, A., Thöne, A.-K., Pramme, L., Blumenthal, N., Li, M., Asché, L., Jonas, S., et al. (2022) · Clinical Psychology Review · doi:10.1016/j.cpr.2022.102213 · Cited by 223
Current advances in digital cognitive assessment for preclinical Alzheimer's disease
Öhman, F., Hassenstab, J., Berron, D., Schöll, M., & Papp, K. V. (2021) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12217 · Cited by 214
Metadata
- Authors
- Allison, S. L., Fagan, A. M., Morris, J. C., & Head, D.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2016-04-26
- Volume
- 52
- Issue
- 1
- Pages
- 77-90
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2288292510
- Cited by
- 208
- References
- 24
- FWCI
- 16.56
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.